Frič Přemysl, Škrha Jan, Šedo Aleksi, Bušek Petr, Laclav Martin, Bunganič Bohuš, Zavoral Miroslav
aGastroenterology Unit, Department of Medicine, Military University Hospital bLaboratory of Endocrinology and Metabolism cInstitute of Biochemistry and Experimental Oncology, First Faculty of Medicine, General University Hospital, and Charles University, Prague, Czech Republic.
Eur J Gastroenterol Hepatol. 2017 Mar;29(3):e13-e18. doi: 10.1097/MEG.0000000000000810.
Pancreatic cancer (PC) behaves very differently in comparison with other malignancies. Its incidence has been increasing continuously; mortality has not decreased, the diagnosis is frequently late, radical surgery is performed only in 15-20% of patients, and chemotherapy is only palliative. PC occurs in three different forms. Sporadic PC accounts for 90% of all PCs. Its most frequent form is the pancreatic ductal adenocarcinoma. The remaining 10% constitute two minority groups: familial PC (7%) and PC as a manifestation of a genetic cancer syndrome (3%). PCs are preceded by a precancerous lesion (precursor). At present, six different precursors are known. They have different histomorphological characteristics and malignant potential. The recognition and correct interpretation of individual precursors influences adequate clinical decision-making. The publication surveys the present knowledge of individual precursors and their role in the early pancreatic carcinogenesis.
Eur J Gastroenterol Hepatol. 2017-3
Hepatobiliary Pancreat Dis Int. 2020-6
Langenbecks Arch Surg. 2008-7
Arch Pathol Lab Med. 2011-6
Tidsskr Nor Laegeforen. 2006-3-23
Biomolecules. 2022-4-29